GENERATION OF ANTIGEN-SPECIFIC MABS USING SCID-HU MICE

使用 SCID-HU 小鼠生成抗原特异性 MABS

• 批准号: 3489436
• 负责人: KATHLEEN A DENIS
• 金额: $ 4.89万
• 依托单位: SPECIALTY LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-07-01 至 1991-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489436
• 关键词: Borrelia; Epstein Barr virus; active immunization; antibody specificity; antigen antibody reaction; antigen presenting cell; chimeric proteins; diagnosis quality /standard; genetic strain; lymphatic tissue transplantation; lymphocyte; monoclonal antibody

DESCRIPTION: (Adapted from the applicant's abstract) The overall goal of this work is to develop an adoptive immunization scheme using SCID mice reconstituted with human peripheral blood lymphocytes to generate antigen-specific human MAbs, SCID mice will be pretreated with cytotoxic agents to give improved levels of early human cell reconstitution. These SCID-hu mice will then be immunized with either sonicated or live Borrelia burgdorferi and human antibody responses monitored. SCID-hu mice producing antigen specific antibodies will be sacrificed and the chimeric tissues transformed with EBV. This step will select out human B lymphocytes from the mixture, activate and transform them. Lymphoblastoid lines producing antigen-specific human antibodies will be stabilized and immortalized by hybridization with a mouse-human heteromyeloma line. It is hoped that this will lead to a general method of human cell immunization and human MAb formation. These HMAbs can be utilized as international standards for clinical diagnostic assays.

描述：（根据申请人的摘要改编）的总体目标 这项工作是使用SCID小鼠制定收养免疫计划 用人外周血淋巴细胞重组以产生 抗原特异性人物mAb，SCID小鼠将用细胞毒性预处理 代理人提供改善的早期人类细胞重建水平。 这些 然后，SCID-HU小鼠将用超声或活渗透 监测了Burgdorferi和人类抗体反应。 Scid-hu小鼠产生 将处死抗原特异性抗体并嵌合组织 用EBV转变。 此步骤将从 混合物，激活并改变它们。 产生淋巴母细胞线 抗原特异性的人类抗体将被稳定和永生 与小鼠 - 人类异肌瘤系的杂交。 希望这个 将导致人类细胞免疫和人MAB的一般方法 形成。 这些HMAB可以用作国际标准 临床诊断测定。